JK-06

N/A

Report date: 2025/03/28 10:21:10
First In Class

Base Information

Drug NameJK-06
Drug Alias NameJK-06
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payload
Mechanisms of ActionAnti-Trophoblast glycoproteinTubulin polymerisation inhibitors
TargetsTrophoblast glycoproteinTubulin
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumSpainEU +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesXinlitai (Chengdu) Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSalubris Biotherapeutics IncXinlitai (Chengdu) Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A